OPC 1

Drug Profile

OPC 1

Alternative Names: AST-OPC1; GRNOPC 1; hESC-derived oligodendrocyte progenitor cells (OPC) - Geron/University of California; Oligodendrocyte progenitor cells - Asterias Biotherapeutics; OPC-1

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Geron Corporation
  • Developer Asterias Biotherapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Spinal cord injuries
  • Preclinical Canavan disease; Multiple sclerosis; Stroke
  • Discontinued Alzheimer's disease

Most Recent Events

  • 05 Oct 2017 New 12-month efficacy data from the phase I/IIa SCiSTAR trial in Spinal cord injuries released by Asterias Biotherapeutics
  • 02 Oct 2017 OPC1 receives Regenerative Medicine Advanced Therapy designation from the US FDA
  • 06 Sep 2017 OPC 1 is still in phase I/II development for Spinal cord injuries in USA (Intralesional) (Asterias Biotherapeutics pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top